PT3215530T - Anticorpos de il-6 melhorados - Google Patents

Anticorpos de il-6 melhorados

Info

Publication number
PT3215530T
PT3215530T PT157975384T PT15797538T PT3215530T PT 3215530 T PT3215530 T PT 3215530T PT 157975384 T PT157975384 T PT 157975384T PT 15797538 T PT15797538 T PT 15797538T PT 3215530 T PT3215530 T PT 3215530T
Authority
PT
Portugal
Prior art keywords
antibodies
improved
Prior art date
Application number
PT157975384T
Other languages
English (en)
Portuguese (pt)
Inventor
March SCHMIDT Michael
Tisdale Alison
Steven Furfine Eric
Zarbis-Papastoitsis Grigorios
Original Assignee
Sesen Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sesen Bio Inc filed Critical Sesen Bio Inc
Publication of PT3215530T publication Critical patent/PT3215530T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT157975384T 2014-11-07 2015-11-06 Anticorpos de il-6 melhorados PT3215530T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462077105P 2014-11-07 2014-11-07
US201462087448P 2014-12-04 2014-12-04
US201562247705P 2015-10-28 2015-10-28

Publications (1)

Publication Number Publication Date
PT3215530T true PT3215530T (pt) 2019-11-21

Family

ID=54602042

Family Applications (2)

Application Number Title Priority Date Filing Date
PT231893850T PT4268843T (pt) 2014-11-07 2015-11-06 Anticorpos contra il-6 melhorados
PT157975384T PT3215530T (pt) 2014-11-07 2015-11-06 Anticorpos de il-6 melhorados

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT231893850T PT4268843T (pt) 2014-11-07 2015-11-06 Anticorpos contra il-6 melhorados

Country Status (33)

Country Link
US (3) US11142571B2 (en:Method)
EP (3) EP3632931A1 (en:Method)
JP (1) JP6594438B2 (en:Method)
KR (2) KR102636726B1 (en:Method)
CN (1) CN107249631B (en:Method)
AU (1) AU2015342882B2 (en:Method)
CA (1) CA2965689C (en:Method)
CL (1) CL2017001135A1 (en:Method)
CO (1) CO2017005404A2 (en:Method)
CR (1) CR20170231A (en:Method)
DK (2) DK3215530T3 (en:Method)
EA (1) EA035199B1 (en:Method)
ES (2) ES2756275T3 (en:Method)
FI (1) FI4268843T3 (en:Method)
HR (2) HRP20251312T1 (en:Method)
HU (1) HUE046181T2 (en:Method)
IL (1) IL251858B (en:Method)
LT (1) LT4268843T (en:Method)
MA (2) MA62787B1 (en:Method)
MX (2) MX385206B (en:Method)
MY (1) MY185114A (en:Method)
PE (1) PE20171107A1 (en:Method)
PH (1) PH12017500809B1 (en:Method)
PL (2) PL3215530T3 (en:Method)
PT (2) PT4268843T (en:Method)
RS (2) RS59805B1 (en:Method)
SA (1) SA517381458B1 (en:Method)
SG (2) SG11201703574VA (en:Method)
SI (1) SI3215530T1 (en:Method)
SM (1) SMT202500415T1 (en:Method)
UA (1) UA122673C2 (en:Method)
WO (1) WO2016073890A1 (en:Method)
ZA (1) ZA201702985B (en:Method)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42924A (fr) 2015-09-23 2018-08-01 Hoffmann La Roche Variants optimisés d'anticorps anti-vegf
EP3419599A4 (en) * 2016-02-23 2019-09-11 Sesen Bio, Inc. IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
CN110291108A (zh) * 2016-12-19 2019-09-27 格兰马克药品股份有限公司 新型tnfr激动剂及其用途
UA129242C2 (uk) 2017-03-22 2025-02-26 Дженентек, Інк. Оптимізована композиція антитіла для лікування захворювань очей
SG11201908547VA (en) 2017-03-22 2019-10-30 Genentech Inc Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
CN109867723B (zh) * 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途
EP4118114A1 (en) 2020-03-13 2023-01-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
PH12022552267A1 (en) 2020-03-24 2024-02-19 Genentech Inc Tie2-binding agents and methods of use
AU2021360935A1 (en) 2020-10-15 2023-05-25 F. Hoffmann-La Roche Ag Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics
CN116554298A (zh) * 2022-02-25 2023-08-08 南京工业大学 一种强化细菌卷曲菌毛提高人表皮生长因子分泌生产效率的方法
CN115343483B (zh) * 2022-08-12 2024-11-26 苏州邦器生物技术有限公司 一种自身免疫性糖尿病检测用试剂盒及其制备方法
CA3264497A1 (en) * 2022-10-24 2024-05-02 F. Hoffmann-La Roche Ag Predicting response to il-6 antagonists

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
CA2105300C (en) 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
FR2734739B1 (fr) 1995-06-01 1997-07-11 Gec Alsthom Stein Ind Dispositif de surveillance d'un broyeur a boulets
TW311927B (en:Method) 1995-07-11 1997-08-01 Minnesota Mining & Mfg
EP0795743A3 (en) 1996-03-15 1998-02-25 Japan Tobacco Inc. Method and apparatus for infra-red moisture measurement
US5839430A (en) 1996-04-26 1998-11-24 Cama; Joseph Combination inhaler and peak flow rate meter
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6358058B1 (en) 1998-01-30 2002-03-19 1263152 Ontario Inc. Aerosol dispensing inhaler training device
ATE439592T1 (de) 1998-12-10 2009-08-15 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
TWI313299B (en) 2000-11-30 2009-08-11 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
WO2002088171A2 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
PT1441589E (pt) 2001-11-08 2012-08-13 Abbott Biotherapeutics Corp Formulação farmacêutica líquida estável de anticorpos igg
KR20100120243A (ko) 2002-05-07 2010-11-12 피시비다 유에스 인코포레이티드 약물 전달 장치를 형성하는 공정
WO2004045507A2 (en) * 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
WO2005062955A2 (en) 2003-12-23 2005-07-14 Rinat Neuroscience Corp. Agonist anti-trkc antibodies and methods using same
DK2213683T3 (da) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT-Fc-REGIONER
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP2009521909A (ja) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ＩＬ−６とＩＬ−６Ｒαの複合体のｇｐ１３０への結合を阻害する抗ＩＬ−６抗体
WO2007104529A2 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
JP5607357B2 (ja) 2006-05-19 2014-10-15 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 抗原特異的ｂ細胞のクローン集団を獲得するための培養方法
EP3187506B1 (en) * 2007-05-21 2019-03-27 AlderBio Holdings LLC Antibodies to il-6 and use thereof
AU2008299885C1 (en) 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
KR20100099193A (ko) 2007-11-21 2010-09-10 암젠 인크 Ｗｉｓｅ 결합 항체 및 에피토프
US20100187601A1 (en) 2007-12-12 2010-07-29 Fujio Masuoka Semiconductor device
AU2009204863B2 (en) 2008-01-15 2015-07-16 AbbVie Deutschland GmbH & Co. KG Powdered protein compositions and methods of making same
SI2328616T1 (sl) 2008-08-05 2015-08-31 Novartis Ag Sestavki in postopki za protitelesa proti komplementnemu proteinu C5
KR101546996B1 (ko) 2008-09-12 2015-08-24 가부시키가이샤 케이디에프 분수장치
WO2010039750A2 (en) 2008-10-01 2010-04-08 Monsanto Technology Llc Transgenic plants with enhanced agronomic traits
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
CA2744055A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
MX337590B (es) 2009-01-29 2016-03-11 Medimmune Llc Anticuerpos anti il-6 humanos, con semivida in vivo prolongada y su uso en el tratamiento de oncologia, enfermedades autoinmunes y enfermedades inflamatorias.
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CN103096933A (zh) 2010-07-12 2013-05-08 CovX科技爱尔兰有限公司 多功能抗体缀合物
CN104428315B (zh) 2012-07-13 2017-09-29 罗氏格黎卡特股份公司 双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
US20150239970A1 (en) 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
CN104903349B (zh) * 2012-11-08 2018-10-19 十一生物治疗股份有限公司 Il-6拮抗剂及其应用
SG10201912985RA (en) 2013-07-12 2020-02-27 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention

Also Published As

Publication number Publication date
PH12017500809A1 (en) 2017-10-02
JP2017535285A (ja) 2017-11-30
CA2965689A1 (en) 2016-05-12
IL251858B (en) 2022-09-01
MX2021008663A (es) 2021-08-19
SA517381458B1 (ar) 2020-07-09
EP3215530B9 (en) 2020-09-09
ES3051832T3 (en) 2025-12-30
WO2016073890A1 (en) 2016-05-12
CO2017005404A2 (es) 2017-10-31
US11142571B2 (en) 2021-10-12
PE20171107A1 (es) 2017-08-07
EP3215530B1 (en) 2019-08-21
SG11201703574VA (en) 2017-05-30
IL251858A0 (en) 2017-06-29
EA035199B1 (ru) 2020-05-14
KR20170077196A (ko) 2017-07-05
KR102636726B1 (ko) 2024-02-13
PL3215530T3 (pl) 2020-05-18
BR112017008672A2 (pt) 2018-03-20
ZA201702985B (en) 2019-10-30
US20250059270A1 (en) 2025-02-20
PL4268843T3 (pl) 2025-12-15
HRP20191945T1 (hr) 2020-01-24
MY185114A (en) 2021-04-30
JP6594438B2 (ja) 2019-10-23
EP4268843A2 (en) 2023-11-01
CL2017001135A1 (es) 2017-12-15
AU2015342882A1 (en) 2017-05-18
EP4268843A3 (en) 2023-12-27
MA51554A (fr) 2020-11-18
RS67353B1 (sr) 2025-11-28
SG10202103420PA (en) 2021-05-28
ES2756275T3 (es) 2020-04-27
AU2015342882B2 (en) 2021-05-20
MX385206B (es) 2025-03-14
CN107249631A (zh) 2017-10-13
DK4268843T3 (da) 2025-11-10
SMT202500415T1 (it) 2026-01-12
US20190194312A1 (en) 2019-06-27
FI4268843T3 (fi) 2025-11-14
LT4268843T (lt) 2025-11-25
ES2756275T9 (es) 2020-10-29
EP3215530A1 (en) 2017-09-13
KR102770849B1 (ko) 2025-02-20
PT4268843T (pt) 2025-10-31
CR20170231A (es) 2017-09-25
EP3632931A1 (en) 2020-04-08
KR20240023450A (ko) 2024-02-21
HK1244008A1 (en) 2018-07-27
MA62787B1 (fr) 2025-11-28
RS59805B1 (sr) 2020-02-28
EA201791005A1 (ru) 2017-09-29
DK3215530T3 (da) 2019-11-25
HUE046181T2 (hu) 2020-02-28
MX2017005992A (es) 2017-09-15
US20220169719A1 (en) 2022-06-02
UA122673C2 (uk) 2020-12-28
SI3215530T1 (sl) 2020-02-28
CA2965689C (en) 2022-03-22
PH12017500809B1 (en) 2023-09-20
NZ731090A (en) 2024-03-22
EP4268843B1 (en) 2025-09-03
HRP20251312T1 (hr) 2025-12-05
CN107249631B (zh) 2021-11-23

Similar Documents

Publication Publication Date Title
NL301117I1 (nl) trastuzumab deruxtecan
IL251963A0 (en) Anti-pd-1 antibodies
DK3344654T3 (da) Anti-lag-3-antistoffer
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
DK3126395T3 (da) Multispecifikke antistoffer
DK3160994T3 (da) Multispecifikke antigenbindende proteiner
HUE060878T2 (hu) Anti-transztiretin antitestek
DK3250593T3 (da) Anti-transthyretin-antistoffer
CL2016001742A1 (es) Anticuerpos anti-baff novedosos
IL256099A (en) Antibody
IL291164A (en) Anti-nme antibody
PT3215530T (pt) Anticorpos de il-6 melhorados
LT3092003T (lt) Naujas anti-netrino-1 antikūnas
IL257368A (en) Antibody
DK3484921T3 (da) Anti-IL-22R antistoffer
DK3452515T3 (da) Her-2-bindende antistoffer
HUE054148T2 (hu) Anti-ORAI1 antitest
LT3126391T (lt) Hpa-1a antikūnai
LT3628731T (lt) Naujas antipresepsino antikūnas
ITUB20155097A1 (it) Anticorpi umanizzati anti-BAG3